PropertyValue
?:abstract
  • OBJECTIVE: No data are available to develop uniform recommendations for reperfusion therapies in ST-segment elevation myocardial infarction (STEMI) during the coronavirus disease 2019 (COVID-19) pandemic. We aimed to fill the evidence gap regarding STEMI reperfusion strategy during the COVID-19 era. METHODS: Clinical characteristics and outcomes for 17 patients with STEMI who received fibrinolysis during the COVID-19 pandemic were compared with 20 patients who received primary percutaneous coronary intervention (PPCI), and were further compared with another 41 patients who received PPCI in the pre-COVID-19 period. RESULTS: In patients with STEMI, fibrinolysis achieved a comparable in-hospital and 30-day primary composite end point, as compared with those who received PPCI during the COVID-19 pandemic. No major bleeding was detected in either group. Compared patients with STEMI who received PPCI in the pre-COVID-19 period, we found a remarkable extension of chest pain onset-to-first medical contact (FMC) and FMC-to-wire crossing times, significantly increased number and length of stents, and much worse thrombolysis in myocardial infarction flow in patients with STEMI who received PPCI during the COVID-19 pandemic. CONCLUSION: Owing to its considerable efficacy and safety and advantages in conserving medical resources, we recommend fibrinolysis as a reasonable alternative for STEMI care during the COVID-19 pandemic.
is ?:annotates of
?:creator
?:doi
?:doi
  • 10.1177/0300060520966151
?:journal
  • J_Int_Med_Res
?:license
  • cc-by-nc
?:pdf_json_files
  • document_parses/pdf_json/f7ae10b2a20060b7eed61e6088bdc5d957392ba3.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7645389.xml.json
?:pmcid
?:pmid
?:pmid
  • 33108941.0
?:publication_isRelatedTo_Disease
is ?:relation_isRelatedTo_publication of
?:sha_id
?:source
  • Medline; PMC
?:title
  • Fibrinolysis is a reasonable alternative for STEMI care during the COVID-19 pandemic
?:type
?:year
  • 2020-10-27

Metadata

Anon_0  
expand all